EP0941120A4 - Branched peptide linkers - Google Patents
Branched peptide linkersInfo
- Publication number
- EP0941120A4 EP0941120A4 EP97946428A EP97946428A EP0941120A4 EP 0941120 A4 EP0941120 A4 EP 0941120A4 EP 97946428 A EP97946428 A EP 97946428A EP 97946428 A EP97946428 A EP 97946428A EP 0941120 A4 EP0941120 A4 EP 0941120A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide linkers
- branched peptide
- branched
- linkers
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3036796P | 1996-11-05 | 1996-11-05 | |
US30367P | 1996-11-05 | ||
PCT/US1997/019851 WO1998019705A1 (en) | 1996-11-05 | 1997-10-31 | Branched peptide linkers |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0941120A1 EP0941120A1 (en) | 1999-09-15 |
EP0941120A4 true EP0941120A4 (en) | 2004-08-18 |
Family
ID=21853889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97946428A Withdrawn EP0941120A4 (en) | 1996-11-05 | 1997-10-31 | Branched peptide linkers |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0941120A4 (en) |
JP (1) | JP2001505194A (en) |
AU (1) | AU5159798A (en) |
CA (1) | CA2264610A1 (en) |
WO (1) | WO1998019705A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2264227A1 (en) * | 1996-09-27 | 1998-04-02 | Raymond A. Firestone | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
AU733495B2 (en) | 1996-10-28 | 2001-05-17 | Nycomed Imaging As | Improvements in or relating to diagnostic/therapeutic agents |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
WO1999025729A1 (en) * | 1997-11-18 | 1999-05-27 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
EA003398B1 (en) * | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Drug complex with polymeric carrier |
WO2000025825A1 (en) | 1998-10-30 | 2000-05-11 | Daiichi Pharmaceutical Co., Ltd. | Dds compounds and method for assaying the same |
JP4808846B2 (en) * | 1999-02-24 | 2011-11-02 | ザ ユーエイビー リサーチ ファンデイション | Taxane derivatives for targeted treatment of cancer |
EP1176985A2 (en) * | 1999-04-28 | 2002-02-06 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
DE60032633T2 (en) * | 1999-11-24 | 2007-10-04 | Immunogen Inc., Cambridge | CYTOTOXIC AGENTS CONTAINING TAXANE AND ITS THERAPEUTIC APPLICATION |
DE10048417A1 (en) * | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Branched linker connections |
WO2002076448A1 (en) | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
JP4342314B2 (en) * | 2001-12-17 | 2009-10-14 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | Cleavage agents for specific delivery to the lesion site |
KR20050032110A (en) | 2002-08-02 | 2005-04-06 | 이뮤노젠 아이엔씨 | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
AU2003256038A1 (en) * | 2002-08-30 | 2004-03-19 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
AU2003282624A1 (en) | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
WO2004081538A2 (en) | 2003-03-13 | 2004-09-23 | Irm, Llc | Compositions and methods of vinyl oxazolone polymerization |
US20040228831A1 (en) * | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
JP2007501014A (en) * | 2003-08-05 | 2007-01-25 | ウイスコンシン アラムニ リサーチ ファンデーション | Targeted carrier fusion for delivery of chemotherapeutic agents |
WO2006074397A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Cripto binding molecules |
AU2007303205A1 (en) | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
NZ626620A (en) | 2012-01-10 | 2016-07-29 | Biogen Ma Inc | Enhancement of transport of therapeutic molecules across the blood brain barrier |
WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6895254B2 (en) | 2013-12-16 | 2021-06-30 | ジェネンテック, インコーポレイテッド | Peptidomimetic compounds and their antibodies-drug conjugates |
CA2928952A1 (en) * | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
SG10202001468UA (en) | 2014-02-17 | 2020-04-29 | Seattle Genetics Inc | Hydrophilic antibody-drug conjugates |
EP3129065A4 (en) | 2014-03-12 | 2018-01-24 | Invictus Oncology Pvt. Ltd. | Targeted drug delivery through affinity based linkers |
KR101628872B1 (en) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | Compounds comprising self-immolative group |
EP3307780A1 (en) | 2015-06-15 | 2018-04-18 | Genentech, Inc. | Antibodies and immunoconjugates |
CN107847606A (en) | 2015-11-25 | 2018-03-27 | 乐高化学生物科学股份有限公司 | Include the conjugate and its correlation technique from group of degrading |
CA3006247A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
KR20180078329A (en) | 2015-11-25 | 2018-07-09 | 주식회사 레고켐 바이오사이언스 | Antibody-drug conjugates comprising branched linkers and methods for their preparation |
BR112019020136A2 (en) | 2017-03-29 | 2020-04-22 | Legochem Biosciences Inc | prodrug of pyrrolobenzodiazepine dimer and compound of ligand-ligand conjugate of the same |
SG11202007540SA (en) | 2018-02-20 | 2020-09-29 | Seattle Genetics Inc | Hydrophobic auristatin f compounds and conjugates thereof |
BR112020022299A2 (en) | 2018-05-09 | 2021-02-23 | Legochem Biosciences, Inc. | compositions and methods related to anti-cd19 antibody-drug conjugates |
KR20210028544A (en) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use |
WO2022029420A1 (en) | 2020-08-03 | 2022-02-10 | Bicycletx Limited | Peptide-based linkers |
EP4222257A1 (en) | 2020-09-30 | 2023-08-09 | F. Hoffmann-La Roche AG | Bacterial pilus protein complex fimgt-dsf stabilized protein complexes for producing filamentous phages |
JPWO2022255425A1 (en) * | 2021-06-01 | 2022-12-08 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084560A (en) * | 1986-06-30 | 1992-01-28 | Oncogen | Immunoconjugates and methods for their use in tumor therapy |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5563250A (en) * | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
US5017693A (en) * | 1987-12-02 | 1991-05-21 | Neorx Corporation | Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound |
IL89220A (en) * | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
IT1240643B (en) * | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | BIOLOGICALLY ACTIVE PEPTIDES CONTAINING IN 2-ALCHYL TRIPTOFANE CHAIN |
US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
DE69226431T2 (en) * | 1991-04-05 | 1999-04-22 | Univ Washington | CELL RECEPTOR SPECIFIC MONOCLONAL ANTIBODIES AGAINST STEM CELL FACTOR RECEPTOR |
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
-
1997
- 1997-10-31 WO PCT/US1997/019851 patent/WO1998019705A1/en active Application Filing
- 1997-10-31 AU AU51597/98A patent/AU5159798A/en not_active Abandoned
- 1997-10-31 CA CA002264610A patent/CA2264610A1/en not_active Abandoned
- 1997-10-31 JP JP52160698A patent/JP2001505194A/en not_active Ceased
- 1997-10-31 EP EP97946428A patent/EP0941120A4/en not_active Withdrawn
Non-Patent Citations (5)
Title |
---|
DUBOWCHIK GENE M ET AL: "Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 11, 3 June 2002 (2002-06-03), pages 1529 - 1532, XP002284221, ISSN: 0960-894X * |
KING H D ET AL: "Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.", BIOCONJUGATE CHEMISTRY. UNITED STATES 1999 MAR-APR, vol. 10, no. 2, March 1999 (1999-03-01), pages 279 - 288, XP002284220, ISSN: 1043-1802 * |
See also references of WO9819705A1 * |
SHIH L B ET AL: "ANTHRACYCLINE IMMUNOCONJUGATES PREPARED BY A SITE-SPECIFIC LINKAGE VIA AN AMINODEXTRAN INTERMEDIATE CARRIER", CANCER RESEARCH, vol. 51, no. 16, 1991, pages 4192 - 4198, XP001181850, ISSN: 0008-5472 * |
WILLNER DAVID ET AL: "(6-Maleimidocaproyl)hydrazone of doxorubicin-A new derivative for the preparation of immunoconjugates of doxorubicin", BIOCONJUGATE CHEMISTRY, vol. 4, no. 6, 1993, pages 521 - 527, XP002284219, ISSN: 1043-1802 * |
Also Published As
Publication number | Publication date |
---|---|
AU5159798A (en) | 1998-05-29 |
EP0941120A1 (en) | 1999-09-15 |
JP2001505194A (en) | 2001-04-17 |
CA2264610A1 (en) | 1998-05-14 |
WO1998019705A1 (en) | 1998-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0941120A4 (en) | Branched peptide linkers | |
EP0977579A4 (en) | Gastrin receptor-avid peptide conjugates | |
HRP970308B1 (en) | Peptide derivatives | |
GB9702377D0 (en) | Peptide derivatives | |
PL318017A1 (en) | Peptides | |
GB9718110D0 (en) | Peptides | |
GB9624562D0 (en) | Peptide derivatives | |
GB9700154D0 (en) | Peptides | |
GB9425380D0 (en) | Peptides | |
GB9627114D0 (en) | Multiple branch peptide constructions | |
EP0996457A4 (en) | Fsh-releasing peptides | |
EP0935608A4 (en) | Cytotoxic peptides | |
GB9519511D0 (en) | Peptides | |
GB9613705D0 (en) | Novel peptides | |
AUPO324096A0 (en) | Linker peptide | |
GB9425381D0 (en) | Peptides | |
GB9612648D0 (en) | Peptides | |
GB9626362D0 (en) | Peptides | |
GB9625227D0 (en) | Peptides | |
GB9606765D0 (en) | Peptides | |
GB9608430D0 (en) | Peptides | |
SG55039A1 (en) | Peptides | |
GB9605904D0 (en) | Peptides | |
GB9611881D0 (en) | Peptide derivatives | |
GB9709607D0 (en) | Peptide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990607 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07K 5/08 B Ipc: 7C 07K 5/10 B Ipc: 7C 07K 5/06 B Ipc: 7A 61K 47/48 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040701 |
|
17Q | First examination report despatched |
Effective date: 20050801 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090310 |